<DOC>
	<DOCNO>NCT00005091</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness DX-8951f treating patient previously untreated stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>DX-8951f Treating Previously Untreated Patients With Stage IIIB Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity DX-8951f previously untreated patient stage IIIB IV non-small cell lung cancer . II . Evaluate quantitative qualitative toxic effect regimen patient . III . Evaluate pharmacokinetics regimen patient . IV . Assess time progression survival status patient . OUTLINE : This multicenter study . Patients receive DX-8951f IV 30 minute daily 5 day . Treatment repeat every 3 week maximum 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month survival . PROJECTED ACCRUAL : A total 12-37 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable , metastatic , recurrent nonsmall cell lung cancer Stage IIIB IV Measurable disease No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis present ) Renal : Creatinine great 2.0 mg/dL Cardiovascular : No active congestive heart failure Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent serious infection No malignancy within past 5 year except nonmelanomatous skin cancer No overt psychosis , mental disability , incompetence No life threaten illness PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy great 25 % bone marrow No concurrent radiotherapy Surgery : No concurrent surgery Other : At least 28 day since prior investigational drug No concurrent investigational drug within 28 day final dose study drug No concurrent drug induce inhibit CYP3A enzyme</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>